These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31597860)

  • 1. [Hematopoietic cell transplantation for chronic active EBV infection].
    Inoue M
    Rinsho Ketsueki; 2019; 60(9):1331-1336. PubMed ID: 31597860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study.
    Watanabe Y; Sasahara Y; Satoh M; Looi CY; Katayama S; Suzuki T; Suzuki N; Ouchi M; Horino S; Moriya K; Nanjyo Y; Onuma M; Kitazawa H; Irie M; Niizuma H; Uchiyama T; Rikiishi T; Kumaki S; Minegishi M; Wada T; Yachie A; Tsuchiya S; Kure S
    Eur J Haematol; 2013 Sep; 91(3):242-248. PubMed ID: 23734904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
    Cohen JI; Jaffe ES; Dale JK; Pittaluga S; Heslop HE; Rooney CM; Gottschalk S; Bollard CM; Rao VK; Marques A; Burbelo PD; Turk SP; Fulton R; Wayne AS; Little RF; Cairo MS; El-Mallawany NK; Fowler D; Sportes C; Bishop MR; Wilson W; Straus SE
    Blood; 2011 Jun; 117(22):5835-49. PubMed ID: 21454450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein-Barr virus-associated T or natural killer cell lymphoproliferative diseases.
    Sawada A; Inoue M; Koyama-Sato M; Kondo O; Yamada K; Shimizu M; Isaka K; Kimoto T; Kikuchi H; Tokimasa S; Yasui M; Kawa K
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):214-21. PubMed ID: 24188918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How we treat chronic active Epstein-Barr virus infection.
    Sawada A; Inoue M; Kawa K
    Int J Hematol; 2017 Apr; 105(4):406-418. PubMed ID: 28210942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation.
    Okamura T; Hatsukawa Y; Arai H; Inoue M; Kawa K
    Lancet; 2000 Jul; 356(9225):223-4. PubMed ID: 10963205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
    Kawa K; Okamura T; Yasui M; Sato E; Inoue M
    Crit Rev Oncol Hematol; 2002 Dec; 44(3):251-7. PubMed ID: 12467965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK-cell post-transplant lymphoproliferative disease successfully treated by second allogenic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus infection.
    Shibata S; Takiuchi Y; Kawasaki N; Okamoto Y; Inano S; Fukunaga A; Tabata S; Arai A; Imadome KI; Kitano T
    Int J Hematol; 2022 Apr; 115(4):595-599. PubMed ID: 35001347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active epstein-barr virus infection.
    Nakagawa M; Hashino S; Takahata M; Kawamura T; Fujisawa F; Kahata K; Kondo T; Imamura M; Ando S; Asaka M;
    Int J Hematol; 2007 Jun; 85(5):443-5. PubMed ID: 17562623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical features of adult-onset chronic active Epstein-Barr virus infection].
    Kawamoto K; Miyoshi H; Seto M; Kimura H; Ohshima K
    Rinsho Ketsueki; 2019; 60(8):944-952. PubMed ID: 31484894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection.
    Kawa K; Sawada A; Sato M; Okamura T; Sakata N; Kondo O; Kimoto T; Yamada K; Tokimasa S; Yasui M; Inoue M
    Bone Marrow Transplant; 2011 Jan; 46(1):77-83. PubMed ID: 20498651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency?
    Kimura H
    Rev Med Virol; 2006; 16(4):251-61. PubMed ID: 16791843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
    Okamura T; Kishimoto T; Inoue M; Honda M; Yamashita N; Wakiguchi H; Yagita M; Hosoi G; Sako M; Yasui M; Yagi K; Kawa K
    Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of melphalan dose during reduced-intensity conditioning on engraftment of cord blood transplantation for chronic Epstein-Barr virus-associated T or NK cell lymphoproliferative diseases.
    Mayumi A; Sawada A; Sato M; Shimizu M; Ioi A; Higuchi K; Yasui M; Kawa K; Inoue M
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28536. PubMed ID: 32564520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders.
    Sawada A; Inoue M
    Front Pediatr; 2018; 6():334. PubMed ID: 30460216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.
    Onishi Y; Onodera K; Fukuhara N; Kato H; Ichikawa S; Fujiwara T; Yokoyama H; Yamada-Fujiwara M; Harigae H
    Int J Hematol; 2022 Jun; 115(6):873-881. PubMed ID: 35274195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection.
    Uehara T; Nakaseko C; Hara S; Harima A; Ejiri M; Yokota A; Saito Y; Nishimura M
    Am J Hematol; 2004 Aug; 76(4):368-72. PubMed ID: 15282671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.